Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433457 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of CC-292
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02433457 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 24 participants.
The verdict
NCT02433457, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To evaluate the PK profile of the newly developed CC-292 SDD formulation compared to CC-292 P22 tablet.
Interventions
- DRUG CC-292
- DRUG Oral Omeprazole (OMP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-05-26 |
| Est. Completion | 2014-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02433457
The ClinicalTrials.gov registry entry for NCT02433457 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CC-292 is the first listed.
NCT02433457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02433457 about?
NCT02433457 is a clinical study titled "Relative Bioavailability Study of CC-292". To evaluate the PK profile of the newly developed CC-292 SDD formulation compared to CC-292 P22 tablet.
What is the current status of trial NCT02433457?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-05-26. Estimated completion is 2014-09-26.
What interventions are being tested in trial NCT02433457?
The interventions under investigation include: CC-292 (DRUG), Oral Omeprazole (OMP) (DRUG).
Who is sponsoring clinical trial NCT02433457?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.